Keryx Biopharmaceuticals (KERX +4.2%) is trading higher after saying an article on phase 2...

|About: Keryx Biopharmaceuticals, Inc. (KERX)|By:, SA News Editor

Keryx Biopharmaceuticals (KERX +4.2%) is trading higher after saying an article on phase 2 activity of its drug KRX-0401 has been selected for publication in the October 3 online edition of the Journal of Clinical Oncology. The drug is used to treat patients with refractory, advanced colorectal cancer.